1. Home
  2. Earnings Beat
  3. Abbott Gets FDA Nod for Two Glucose Monitoring Systems

Abbott Gets FDA Nod for Two Glucose Monitoring Systems


Abbott (NYSE: ABT) announced that Lingo and Libre Rio, two of its glucose monitoring system, have received FDA clearance. Lingo and Libre Rio are based on Abbott’s own Freestyle Libre continuous glucose monitoring (CGM) technology.

The latest development is expected to expand the company’s Diabetes Care business.

More in the News

Both the consumer biowearable devices are designed to cater to different needs. Lingo is for consumers who are 18 years or older and want a better understanding about their metabolic health, including personalized coaching to promote lifestyle changes. Libre Rio is for consumption by adults aged 18 or above with Type 2 diabetes, who do not use insulin and maintain their health through lifestyle alterations.

About Lingo

Lingo is designed for the population intending to improve health and wellness. The device consists of biosensor and needs to be worn on upper arm for 14 days. It will then track glucose levels from the body’s reaction to different foods consumed, exercise and daily stressors. The device is linked with a coaching application on a smartphone, which will provide necessary customized advice for consumers’ better health and well-being.

In this regard, Abbott noted that as per a study by the University of North Carolina, just 12% of Americans are metabolically healthy based on five key indicators of metabolic health, including glucose levels, suggesting that most of the U.S. population has room to improve their metabolism. This reflects the huge potential for Lingo.

Further, the device is expected to witness huge market acceptance. This is because, according to a recent online consumer survey by The Harris Poll (on behalf of Abbott), …

Full story available on Benzinga.com

Visited 5 times, 1 visit(s) today